Cancer is a lucrative area for drug developers, and a company that develops therapies to improve clinical outcome of cancer patients is eyeing a public listing.
The IPO Terms
Wilmette, Illinois-based Monopar Therapeutics, Inc. has set the size and price of its previously announced IPO through an amendment to the Form S-1 registration statement filed with the SEC on Sep. 10.
The company is planning a 4.45-million share IPO, estimated to be priced between $8 and $10 per share.
At the midpoint of the estimated price range of $9, the size of the offering is $40.05 million.
It has applied for listing its shares on the Nasdaq under the ticker symbol MNPR.
JonesTrading is serving as the underwriter for the offering.
The Company
Monopar is a clinical-stage biopharma company developing proprietary therapies to improve clinical outcomes for cancer patients. It is building a pipeline through licensing and outright acquisition of oncology assets in late pre-clinical and clinical development.
The company's lead product candidate is Validive, chemically clonidine mucobuccal tablet, with the initiation of a Phase 3 trial for the asset planned for the fourth quarter of 2019.
Source: S-1 filing
The Finances
Monopar doesn't have any commercial product yet and therefore hasn't been reporting revenues. The loss for the fiscal year 2018 widened from $3.23 million in fiscal 2017 to $16.56 million in fiscal 2018.
The loss for the three months ending June 30, 2018 was $821,000 compared to $906,000 in 2019.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
